AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04028804 — intervention group
Intervention type: PROCEDURE
Intervention: FLT PET
Description: The FLT PET scan will be performed 1-5 days after FDG PET in order to ensure consistency between imaging findings. Each patient will receive a single intravenous injection of FLT (5.18 MBq/kg (0.14 mCi/kg)) using a minimum dose of 37 MBq (1 mCi) up to a maximum of 370 MBq (10 mCi) with an accepted 10%-20% variation since dose variation can occur when small concentrated volumes of FLT are being drawn up or radioactive decay has reduced the amount of available.
Study NCT03231995 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.
Description: Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.~Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)
Study NCT02656004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Eucalyptus Oil
Description: Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
Study NCT02656004 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Session
Description: In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
Study NCT02390596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: The dose of Anakinra will be 2mg/kg (patients \<10kg and/or \<8 months: 4mg/kg). If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra 4mg/kg (patients \<10kg and/or \<8 months: 6mg/kg) at day1 instead of 2mg/kg. If the patient does not respond to the 4mg/kg dose at visit 3; d1 within 24 hours, he will receive at visit 4; d2, 6mg/kg of anakinra (patients \<10kg and/or \<8 months: 8mg/kg). Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
Study NCT02527746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
Study NCT02527746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC regimen
Description: Epirubicin 100 mg/m\^2 (in vein) and Cyclophosphamide 600 mg/m\^2 (in vein) on Day 1 of each cycle for 4 cycles.
Study NCT01583309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: online pre-dilution hemofiltration
Description: Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
Study NCT01583309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: online pre-dilution hemodiafiltration
Description: Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
Study NCT03892044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO
Study NCT03892044 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT00481351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20mg plus ezetimibe 10mg
Description: simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
Study NCT00481351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: ezetimiba 10mg once a day
Study NCT00481351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin 20mg
Description: simvastatin 20mg once a day
Study NCT00481351 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 80mg
Description: simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
Study NCT05230706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cephalic helmet
Description: An acrylic headgear (length: 27 cm; width: 27 cm; height: 17.5 cm; opening: 17x12 cm) was placed on the patient's head. The helmet was covered with surgical cloth (green or blue) folded into 50x60cm rectangles, leaving the front part open to maintain adequate airflow.
Study NCT03937895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 'SMT-NK' Inj (allogeneic Natural Killer cell)
Description: In 120 mL, 3x10\^6 (± 20%) cells/kg. weekly administration via Intravenous for 2 weeks. After that, 1 week is a withdrawal period.
Study NCT01403896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plerixafor (Mozobil)
Description: They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
Study NCT01403896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor + G-CSF
Description: They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
Study NCT00384904 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atazanavir/Ritonavir
Description: Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
Study NCT00384904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Famotidine
Description: Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
Study NCT00384904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Famotidine
Description: Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
Study NCT03937895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injection [Keytruda]
Description: Administration via Intravenous of 200 mg every 3 weeks(one administration per cycle.).
Study NCT00101166 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bystander-Based Autologous Tumor Cell Vaccine
Description: The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
Study NCT00384904 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Atazanavir/Ritonavir
Description: Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
Study NCT00384904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Description: Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
Study NCT00384904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine
Description: Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
Study NCT02877875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems
Description: MATCH-ADTC (Chorpita \& Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with Attention-deficit/hyperactivity disorder (ADHD). MATCH is composed of 33 modules-i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
Study NCT02877875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring and Feedback System
Description: For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Feelings Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
Study NCT02877875 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment in the UC condition will use the procedures therapists (e.g., school counselors) and their supervisors consider appropriate and believe to be effective.
Study NCT03652220 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Based Lifestyle Modification
Description: 8 weekly modules, each 3.5 hours of Life ethics, Yoga exercises and Mantra Meditation
Study NCT03652220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Minimal treatment
Description: Drug continuation under medical supervision
Study NCT03652220 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal specific treatment:
Description: Drugs / Psychotherapy / Excercise therapy / Ergotherapy / Relaxation; excl. Yoga, Mantra, MBSR
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline Oral Tablet
Description: Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - >50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline Oral Tablet
Description: Weight Group 16 - 29.9kg: 200mg daily for two weeks; followed by 100mg three times weekly for weeks 3 - 24 Weight Group: 30 - >50kg: 400mg once daily for 14 days followed by 200mg three times weekly for weeks 3 - 24
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid Oral Tablet
Description: Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - >50kg: 600mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delamanid in Oral Dosage Form
Description: Weight Group 16 - 23kg: 25mg twice daily for 24 weeks Weight Group 23.1 - 33.9kg: 50mg twice daily for 24 weeks Weight Group 34 - >50kg: 100mg twice daily for 8 weeks followed by 200 mg daily for 16 weeks
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine Oral Product
Description: Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - >50kg: 100mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin Oral Tablet
Description: Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group >50kg:1000mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid Oral Product
Description: Weight Group 16 - 23kg: 300mg daily Weight Group 23.1 - 50kg: 400mg daily Weight Group >50kg: 600mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol Oral Product
Description: Weight Group 16 - 23kg: 400mg daily Weight Group 23.1 - 29.9kg: 600mg daily Weight Group 30 - 50kg: 800mg daily Weight Group >50kg: 1200mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide Oral Product
Description: Weight Group 16 - 23kg: 750mg daily Weight Group 23.1 - 29.9kg: 1000mg daily Weight Group 30 - 33.9kg: 1250mg daily Weight Group 34 - 50kg: 1500mg daily Weight Group >50kg: 2000mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid Oral Tablet
Description: Weight Group 16 - 23kg: 180 - 210mg (crush 1 tab and mix in 10ml water, administer 3-3.5ml. Discard rest) Weight Group 23.1 - 29.9kg: 300mg daily Weight Group 30 - 33.9kg: 450mg daily Weight Group 34 - >50kg: 600mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clofazimine Oral Product
Description: Weight Group 16 - 23kg: 100mg three times a week or 50mg daily Weight Group 23.1 - >50kg: 100mg daily
Study NCT04062201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Oral Tablet
Description: Weight Group 16 - 23kg: 375 - 500mg daily Weight Group 23.1 - 33.9kg: 500mg once daily Weight Group 34 - 50kg: 750mg daily Weight Group >50kg:1000mg daily
Study NCT01311076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-329
Description: TAK-329 50 mg, tablets, orally, single dose, one day.
Study NCT01311076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-329
Description: TAK-329 200 mg, tablets, orally, single dose, one day.
Study NCT01311076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
Study NCT01311076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: TAK-329 placebo-matching tablets, orally, single dose, one day.
Study NCT02439814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
Study NCT02439814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam low
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam high
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam placebo low
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam placebo low
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam placebo high
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam placebo high
Study NCT02183038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium placebo
Study NCT02975388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7079901
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
Study NCT02975388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO7079901
Description: Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
Study NCT04195243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin Pill
Description: The patient will take one pill, every 24 hr, during 7 days
Study NCT04195243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Pill
Description: The patient will take one pill, every 24 hr, during 7 days
Study NCT04195243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: The patient will take one pill, every 24 hr, during 7 days
Study NCT02504905 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: single TMS pulses at intensities in random order from 0 to 100% (increasing at 5% intervals) of stimulator output at a frequency of 0.1 Hz. Three pulses will be delivered at each intensity. MEPs will be recorded and their amplitudes will be plotted against the corresponding stimulation intensity. This curve will provide three significant parameters: (a) S50 intensity (intensity for which we get a MEP 50 % of its maximal size); (b) estimated resting motor threshold (RMT): the abscissa where the tangent to the slope crosses the x axis; and (c) the maximum MEP ( plateau value).
Study NCT02374268 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program alone
Study NCT02374268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combined exercise program and nutrition supplement
Study NCT01273948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: 1. Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or~2. Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or
Study NCT01273948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon (PEG-IFN)
Description: Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight \<75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
Study NCT00796302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate HCl
Description: For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily.
Study NCT00796302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate HCl
Description: For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.~Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.~One pill is taken once daily.
Study NCT00796302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.~For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day.
Study NCT00796302 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Description: PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
Study NCT00796302 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Management Training (PMT)
Description: PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
Study NCT00796302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
Study NCT01832948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Study NCT01832948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study NCT01832948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Study NCT01832948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Study NCT03859635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: 20 ml
Study NCT03859635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, 0.25%
Description: 10 ml
Study NCT03859635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, 0.5%
Description: 30 ml
Study NCT02374268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist control group